Zacks Research Analysts Increase Earnings Estimates for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY) – Equities researchers at Zacks Research lifted their Q1 2025 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a report released on Wednesday, September 11th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings per share of $1.83 for the quarter, up from their previous estimate of $1.82. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $0.77 per share. Zacks Research also issued estimates for Bristol-Myers Squibb’s Q3 2025 earnings at $1.66 EPS, FY2025 earnings at $7.06 EPS and Q2 2026 earnings at $1.69 EPS.

Other research analysts also recently issued research reports about the company. TD Cowen raised their target price on Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a research note on Monday, August 12th. Deutsche Bank Aktiengesellschaft cut their target price on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research note on Tuesday, July 23rd. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Jefferies Financial Group raised their target price on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research note on Wednesday, August 28th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $45.00 target price on shares of Bristol-Myers Squibb in a research note on Monday, July 22nd. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $54.67.

Bristol-Myers Squibb Trading Down 0.7 %

Shares of BMY opened at $48.25 on Thursday. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $60.58. The business has a 50-day moving average of $46.60 and a 200 day moving average of $46.54. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16. The firm has a market cap of $97.80 billion, a P/E ratio of -15.56, a price-to-earnings-growth ratio of 12.62 and a beta of 0.46.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The company had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. During the same quarter last year, the firm posted $1.75 EPS. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be paid a $0.60 dividend. The ex-dividend date is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.97%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Hedge Funds Weigh In On Bristol-Myers Squibb

A number of large investors have recently added to or reduced their stakes in BMY. ESL Trust Services LLC bought a new position in shares of Bristol-Myers Squibb during the first quarter valued at about $27,000. LGT Financial Advisors LLC boosted its holdings in Bristol-Myers Squibb by 42.7% during the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 227 shares during the period. MFA Wealth Advisors LLC bought a new position in Bristol-Myers Squibb during the 2nd quarter worth approximately $39,000. Fairman Group LLC purchased a new position in Bristol-Myers Squibb in the 4th quarter worth approximately $42,000. Finally, Beach Investment Counsel Inc. PA purchased a new stake in shares of Bristol-Myers Squibb during the second quarter valued at approximately $42,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.